Perennial Allergic Rhinitis Clinical Trial
Official title:
Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 (0.15% Solution) and MP03-33 (0.10% Solution) in Children Ages >6 to <12 With Perennial Allergic Rhinitis
Verified date | May 2012 |
Source | Meda Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study is to compare the effectiveness of an Investigational use of an allergy medication (MP03-33) used to treat perennial allergic rhinitis (PAR) to placebo (a nasal spray that contains no medicine). In addition, the study will also compare the safety and effectiveness of an investigational use of another allergy medication (MP03-36) used to treat perennial allergic rhinitis to placebo.
Status | Completed |
Enrollment | 489 |
Est. completion date | April 2011 |
Est. primary completion date | April 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 6 Years to 12 Years |
Eligibility |
Inclusion Criteria: - Male and female subjects >6-<12, inclusive at the screening visit - At least a 1-year history of PAR - The parent must provide written informed consent and the child must provide written assent. - Willing and able to comply with the study requirements - The presence of immunoglobulin E (IgE)-mediated hypersensitivity to dust mite, cockroach, mold, cat or dog dander, confirmed by a positive response to skin prick testing at the Visit 1. A positive response is defined as a wheal diameter of =5 mm larger than the negative control for the skin prick test. Histamine control must also be positive with a wheal diameter >5 mm larger than the control. If there are prevailing seasonal allergies, the subject must have a negative skin test to the specific allergen. - Screening Visit: Have a 12-hour reflective TNSS of at least 6 out of a possible 12 and a congestion score of =2 or a rhinorrhea score of =2 on Visit 1 - Randomization Visit: to be eligible for entry into the double-blind treatment period, subjects/caregivers must record: 1. at least 3 symptom assessments (either AM or PM score) during the past 3 days of the Lead-In Period or the Day of Randomization: 1. a 12-hour reflective TNSS = 6 2. a 12-hour reflective congestion score of =2 or a rhinorrhea score of =2 2. the total of the seven Lead-In symptom assessments during the past 3 days of the Lead-In Period including the Day of Randomization (Visit 2/Day 1): 1. a 12-hour reflective TNSS = 42 2. a 12-hour reflective congestion score of =14 or a rhinorrhea score of =14 - Must have taken at least 10 doses of study medication during the placebo Lead-In Period - General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer - Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections do not preclude participation). Subjects receiving sublingual immunotherapy are excluded. A 6 month washout period is required following the last dose of sublingual immunotherapy. Exclusion Criteria: - On nasal examination, subjects with superficial nasal mucosal erosion, moderate nasal mucosal erosion, nasal mucosal ulceration, nasal septum perforation (Grade 1B - 4) (see section 8.1.4). - Other nasal disease(s) likely to affect deposition of intranasal medication, such as acute sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal structural abnormalities. - Nasal surgery or sinus surgery within the previous year. - Chronic sinusitis - The use of any investigational drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study - Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (Splenda® brand sweetener) - Females who are pregnant or nursing - Females of childbearing potential who are not abstinent and not practicing a medically acceptable method of contraception - Respiratory tract infections within two weeks prior to Visit 1 - Subjects with significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators are eligible for enrollment. - Chronic obstructive sleep apnea syndrome (clinical diagnosis) - Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that might significantly affect the subject's ability to complete this trial. - Clinically relevant abnormal physical findings within 1 week of randomization which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures - Overnight absences from home for more than 3 nights - Family members of research center or private practice personnel who are directly involved in this study are excluded - Members of the same family cannot enroll in the study at the same time - Subjects who have used the medications or therapies that could interfere with symptom evaluation within the time period specified (see Section 4.0). - Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Clinical Research Atlanta | Atlanta | Georgia |
United States | Isis Clinical Research, LLC | Ausitn | Texas |
United States | Central Texas Clinical Research | Austin | Texas |
United States | Sirius Clinical Research | Austin | Texas |
United States | Chesapeake Clinical Research, Inc | Baltimore | Maryland |
United States | Allergy and Asthma Consultants, LLP | Charleston | South Carolina |
United States | Bernstein Clinical Research Center | Cincinnati | Ohio |
United States | Allergy and Asthma Consultants of NJ-PA, P.C | Collegeville | Pennsylvania |
United States | West Coast Clinical Trials | Costa Mesa | California |
United States | Pharmaceutical Research & Consulting Inc | Dallas | Texas |
United States | Colorado Allergy and Asthma Centers, PC | Denver | Colorado |
United States | Intermountain Clinical Research | Draper | Utah |
United States | Idaho Allergy | Eagle | Idaho |
United States | Western Sky Medical Research | El Paso | Texas |
United States | Gary Steven, MD | Greenfield | Wisconsin |
United States | Clinical Research Institute of Indiana | Indianapolis | Indiana |
United States | Baker Asthma, Allergy and Dermatology Research Center, LLC | Lake Oswego | Oregon |
United States | Allergy, Asthma and Respiratory Care Center | Long Beach | California |
United States | Southern California Research | Mission Viejo | California |
United States | Sneeze, Wheeze and Itch Associates | Normal | Illinois |
United States | Allergy, Asthma & Clinical Research Center | Oklahoma City | Oklahoma |
United States | Oklahoma Institute of Allergy and Asthma | Oklahoma City | Oklahoma |
United States | Joann Blessing-Moore,MD | Palo Alto | California |
United States | Asthma and Allergy Center, PC | Papillion | Nebraska |
United States | Clinical Research Institute | Plymouth | Minnesota |
United States | Allergy Associated Research Center | Portland | Oregon |
United States | North Carolina Clinical Research | Raleigh | North Carolina |
United States | Island Medical Research | Rockville Center | New York |
United States | Capital Allergy and Respiratory Disease Center | Sacramento | California |
United States | Sylvana Research Associates | San Antonio | Texas |
United States | Allergy and Asthma Medical Group and Research Center | San Diego | California |
United States | Allergy & Asthma Associates of Santa Clara Valley Research Cntr | San Jose | California |
United States | Princeton Center for Clinical Research | Skillman | New Jersey |
United States | Marycliff Allergy Specialists | Spokane | Washington |
United States | Bensch Research Associates | Stockton | California |
United States | Toledo Center for Clinical Research | Sylvania | Ohio |
United States | Asthma, Sinus & Allergy Centers, LLC | Warren | New Jersey |
United States | Center for Allergy, Asthma and Immunology | Waterbury | Connecticut |
United States | Respiratory Medicine Research Institute of Michigan | Ypsilanti | Michigan |
Lead Sponsor | Collaborator |
---|---|
Meda Pharmaceuticals |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) for the Entire 28-day Study Period Compared to Placebo | Change from baseline in 12-hour reflective total nasal symptom score (TNSS) for the entire 28-day study period compared to placebo,scored on a 0 to 24 scale with 0 being no symptoms and 24 being severe symptoms. | baseline to 28 Days | No |
Secondary | Change From Baseline in the Instantaneous Total Nasal Symptoms Score (TNSS) for the Entire 28-day Study Period Compared to Placebo | change from baseline in 12-hour instantaneous total nasal symptom score (TNSS) for the entire 28-day study period compared to placebo,scored on a 0 to 24 scale with 0 being no symptoms and 24 being severe symptoms. | baseline to 28 days | No |
Secondary | Change From Baseline in 12-hour Reflective Total Ocular Symptoms Score (TOSS) and Instantaneous Total Ocular Symptoms Score (TOSS) for the Entire 28-day Study Period Compared to Placebo | change from baseline in 12-hour instantaneous total ocular symptom score (TOSS) for the entire 28-day study period compared to placebo,scored on a 0 to 18 scale with 0 being no symptoms and 18 being severe symptoms. | baseline to 28 days | No |
Secondary | Change From Baseline to Visit 4 in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) Compared to Placebo | change from baseline in the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) compared to placebo for the entire 28-day study period compared to placebo,scored on a 0 to 42 scale with 0 being not troubled at all and 42 being extremely troublesome. | baseline to 28 Days | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01654536 -
A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)
|
Phase 4 | |
Completed |
NCT01221285 -
Development of Cockroach Immunotherapy by the Inner-City Asthma Consortium
|
Phase 1 | |
Completed |
NCT01539304 -
Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis
|
Phase 3 | |
Terminated |
NCT00491374 -
Study of Nasonex® in Improving Sleep Disturbances Related to Perennial Allergic Rhinitis (Study P04909)(TERMINATED)
|
Phase 4 | |
Completed |
NCT00783224 -
A Comparative Study of Mometasone Furoate Nasal Spray and Fluticasone Propionate Nasal Spray in Patients With Perennial Allergic Rhinitis (Study P04512)
|
Phase 3 | |
Completed |
NCT04324918 -
Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT02532179 -
Subcutaneous Immunotherapy for Mouse in Adults
|
Phase 1/Phase 2 | |
Completed |
NCT01451541 -
A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).
|
Phase 3 | |
Enrolling by invitation |
NCT01062139 -
Cosalin® Monotherapy Versus Cosalin® and Xarlin® Combination Therapy
|
Phase 4 | |
Completed |
NCT00405899 -
Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections
|
N/A | |
Completed |
NCT01549340 -
Retrospective Record Review of Adults and Children Advised for Allergen Immunotherapy (MK-7243-022)
|
N/A | |
Completed |
NCT00789555 -
Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis
|
Phase 4 | |
Completed |
NCT00261287 -
Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)
|
Phase 3 | |
Completed |
NCT00974571 -
Montelukast in Perennial Allergic Rhinitis - 2001-2002 Study (0476-246)
|
Phase 3 | |
Completed |
NCT04654702 -
Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.
|
||
Completed |
NCT05122143 -
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
|
N/A | |
Completed |
NCT01380327 -
Biomarkers of Cockroach Sublingual Immunotherapy 2
|
Phase 1/Phase 2 | |
Completed |
NCT01116778 -
the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis
|
Phase 3 | |
Completed |
NCT00359216 -
The Effects of Mometasone Furoate Nasal Spray in Subjects With Sleep-disordered Breathing (SDB) Associated With Perennial Allergic Rhinitis (Study P04726)
|
Phase 4 | |
Completed |
NCT00163514 -
Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)
|
Phase 3 |